Press Releases Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:25:00 17/07/2025 pm IST			5-day change	1st Jan Change
83.54 ^EUR	+0.41%		-0.74%	-10.88%

17/07	SANOFI : JP Morgan reiterates its Neutral rating	ZD
17/07	SANOFI : Gets a Neutral rating from Deutsche Bank	ZD

Press Releases

Press Release: Sanofi announces extension of Blueprint tender offer	17/07	GL
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration	16/07	GL
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juin 2025	09/07	PU
Press release: Availability of the Q2 2025 Aide mémoire	30/06	GL
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy	30/06	GL
Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts	26/06	PR
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation	25/06	GL
Sanofi : Déclaration des transactions sur actions propres	24/06	PU
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma	23/06	GL
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid	20/06	GL
Press release: Sanofi successfully prices €1.5 billion bond issue	17/06	GL
Sanofi: Disclosure of trading in own shares	17/06	PU
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm	17/06	BU
Sanofi - EAACI, Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study	16/06	AQ
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study	15/06	PU
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study	15/06	GL
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2025	10/06	PU
Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care	09/06	AQ
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season	09/06	GL
Media Update: RAD: Dupixent data reinforce use in atopic dermatitis patients with skin of color	08/06	PU
Sanofi: Disclosure of trading in own shares	07/06	PU
Media Update: ISTH: new data highlight innovation from Sanofi’s pipeline in rare diseases	06/06	PU
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan	05/06	GL
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector	03/06	PU
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector	03/06	GL